| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
570,750,000 |
| Market
Cap: |
76.54(M) |
| Last
Volume: |
3,709,408 |
Avg
Vol: |
3,188,549 |
| 52
Week Range: |
$0.1356 - $0.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytoDyn is a clinical-stage biotechnology company focused on the clinical development of treatments for multiple therapeutic indications based on its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor. Leronlimab is being investigated as a viral entry inhibitor for Human Immunodeficiency Virus. Leronlimab is also being studied in oncology, as well as other therapeutic indications, including coronavirus disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Welch David F |
Director |
– • – |
2020-02-21 |
4 |
A |
$0.00 |
$0 |
I/I |
181,967 |
7,254,315 |
|
- |
|
| Welch David F |
Director |
– • – |
2020-02-21 |
4 |
OE |
$0.18 |
$327,541 |
I/I |
1,819,672 |
7,072,348 |
|
- |
|
| Mulholland Michael D |
SVP-Finance |
• – – |
2019-12-24 |
4 |
D |
$0.64 |
$36,443 |
D/D |
(56,942) |
184,081 |
|
- |
|
| Mulholland Michael D |
SVP-Finance |
• – – |
2019-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
153,897 |
241,023 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2019-12-24 |
4 |
D |
$0.64 |
$44,835 |
D/D |
(70,055) |
317,417 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2019-12-24 |
4 |
A |
$0.00 |
$0 |
D/D |
225,983 |
387,472 |
|
- |
|
| Welch David F |
Director |
– • – |
2019-12-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,639,344 |
5,252,676 |
|
- |
|
| Naydenov Jordan G |
Director |
– • – |
2019-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
833,333 |
6,137,823 |
|
- |
|
| Welch David F |
Director |
– • – |
2019-07-31 |
4 |
A |
$0.00 |
$0 |
I/I |
500,000 |
4,502,202 |
|
- |
|
| Welch David F |
Director |
– • – |
2019-07-31 |
4 |
OE |
$0.30 |
$300,000 |
I/I |
1,000,000 |
4,002,202 |
|
- |
|
| Dockery Carl |
Director |
– • – |
2019-06-12 |
4 |
A |
$0.00 |
$0 |
I/I |
712,499 |
9,484,825 |
|
- |
|
| Dockery Carl |
Director |
– • – |
2019-06-12 |
4 |
OE |
$0.30 |
$566,667 |
I/I |
1,425,000 |
8,772,326 |
|
- |
|
| Kelly Scott A. |
Director |
– • – |
2019-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
1,318,170 |
|
- |
|
| Kelly Scott A. |
Director |
– • – |
2019-06-12 |
4 |
OE |
$0.40 |
$20,000 |
D/D |
50,000 |
1,293,170 |
|
- |
|
| Klump Michael A |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
62,500 |
187,500 |
|
- |
|
| Klump Michael A |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
1,749,999 |
100,000 |
|
- |
|
| Klump Michael A |
Director |
– • – |
2019-05-08 |
4 |
OE |
$0.40 |
$50,000 |
D/D |
125,000 |
125,000 |
|
- |
|
| Klump Michael A |
Director |
– • – |
2019-05-08 |
4 |
OE |
$0.30 |
$1,350,000 |
I/I |
3,500,000 |
66,667 |
|
- |
|
| Welch David F |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
I/I |
825,640 |
3,002,202 |
|
- |
|
| Welch David F |
Director |
– • – |
2019-05-08 |
4 |
OE |
$0.40 |
$660,512 |
I/I |
1,651,281 |
2,559,895 |
|
- |
|
| Pestell Richard Md |
Chief Medical Officer |
• • – |
2018-11-16 |
4 |
A |
$0.57 |
$7,280,878 |
I/I |
12,782,440 |
21,124,440 |
|
- |
|
| Pestell Richard Md |
Chief Medical Officer |
• • – |
2018-11-16 |
4 |
A |
$0.57 |
$4,751,603 |
D/D |
8,342,000 |
8,342,000 |
|
- |
|
| Dockery Carl |
Director |
– • – |
2018-11-16 |
4 |
A |
$0.00 |
$0 |
I/I |
7,578,095 |
7,578,095 |
|
- |
|
| Mulholland Michael D |
CFO, Treasurer and Secretary |
• – – |
2018-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
87,126 |
87,126 |
|
- |
|
| Gould Gregory A |
Director |
– • – |
2018-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
19,176 |
19,176 |
|
- |
|
169 Records found
|
|
Page 5 of 7 |
|
|
